Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review
The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 20...
Gespeichert in:
| Veröffentlicht in: | PloS one 2016-10, Vol.11 (10), p.e0161811-e0161811 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0161811 |
|---|---|
| container_issue | 10 |
| container_start_page | e0161811 |
| container_title | PloS one |
| container_volume | 11 |
| creator | Yang, Ya-Ting Tai, Cheng-Jeng Chen, Chiehfeng Wu, Hong-Cheng Mikhaylichenko, Natalia Chiu, Hsien-Tsai Chen, Yun-Yi Hsu, Yi-Hsin Elsa |
| description | The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL.
The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL.
Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia.
The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL. |
| doi_str_mv | 10.1371/journal.pone.0161811 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1826490466</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A471829448</galeid><doaj_id>oai_doaj_org_article_f6ffaa7d11924243bbbbbebfb1ba6771</doaj_id><sourcerecordid>A471829448</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-55d7707485896d10d8753e667a50c5a6c32854320b2094a7155973b9fb0e55f53</originalsourceid><addsrcrecordid>eNqNk19v0zAUxSMEYmPwDRBYQkLw0GLH_xIekKox2KRJQ9vg1bpJrlNPSVzstNA3Pjru1k0r2gPJQ26c3zm2j3Oz7CWjU8Y1-3Dll2GAbrrwA04pU6xg7FG2z0qeT1RO-eN79V72LMYrSiUvlHqa7eVaM8Y43c_-HLt23q3JZ7fCEJEcWetqqNfEW3IB3QpaJJcBYexxGMk5ti4VkVgf0ksHi4gNua5tgHr0YU2-YXCLOQboyOXkELuOnK77xdz38JHMyMU6jtjD6OqkWTn89Tx7YqGL-GL7PMi-fzm6PDyenJ59PTmcnU5qVebjRMpGa6pFIYtSNYw2hZYcldIgaS1B1TwvpOA5rXJaCtBMylLzqrQVRSmt5AfZ6xvfReej2YYXDStyJUoqlErEyQ3ReLgyi-B6CGvjwZnrAR9aAyEtvENjlbUAumGszEUueLW5sLIVq0ClbJPXp-1sy6rHpk7hpUB2THe_DG5uWr8yMp2RyHUyeLc1CP7nEuNoehfrlCYM6JebdXPJFZWCJvTNP-jDu9tSLaQNuMH6NG-9MTUzoRNYClEkavoAle4Ge1enP826NL4jeL8jSMyIv8cWljGak4vz_2fPfuyyb--xc4RunEffLUfnh7gLihuwDj7GgPYuZEbNplFu0zCbRjHbRkmyV_cP6E502xn8LzKDDSk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826490466</pqid></control><display><type>article</type><title>Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Yang, Ya-Ting ; Tai, Cheng-Jeng ; Chen, Chiehfeng ; Wu, Hong-Cheng ; Mikhaylichenko, Natalia ; Chiu, Hsien-Tsai ; Chen, Yun-Yi ; Hsu, Yi-Hsin Elsa</creator><creatorcontrib>Yang, Ya-Ting ; Tai, Cheng-Jeng ; Chen, Chiehfeng ; Wu, Hong-Cheng ; Mikhaylichenko, Natalia ; Chiu, Hsien-Tsai ; Chen, Yun-Yi ; Hsu, Yi-Hsin Elsa</creatorcontrib><description>The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL.
The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL.
Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia.
The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0161811</identifier><identifier>PMID: 27711130</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Biology and Life Sciences ; Blood ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical trials ; Comparative studies ; Disease-Free Survival ; Drug dosages ; Effectiveness ; Evidence-based medicine ; FDA approval ; Hematology ; Hospitals ; Humans ; Internal medicine ; Lymphocytes T ; Lymphoma ; Lymphoma, T-Cell, Peripheral - therapy ; Lymphomas ; Medical research ; Medicine ; Medicine and Health Sciences ; Monoclonal antibodies ; Neutropenia ; Nitric-oxide synthase ; Online searching ; Patients ; Public health ; Radiation therapy ; Recurrence ; Research and Analysis Methods ; Salvage ; Salvage Therapy - methods ; Stem cells ; Surgery ; Systematic review ; T cells ; T-cell lymphoma ; Targeted cancer therapy ; Thrombocytopenia ; Transplants & implants ; Treatment Outcome</subject><ispartof>PloS one, 2016-10, Vol.11 (10), p.e0161811-e0161811</ispartof><rights>COPYRIGHT 2016 Public Library of Science</rights><rights>2016 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Yang et al 2016 Yang et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-55d7707485896d10d8753e667a50c5a6c32854320b2094a7155973b9fb0e55f53</citedby><cites>FETCH-LOGICAL-c692t-55d7707485896d10d8753e667a50c5a6c32854320b2094a7155973b9fb0e55f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053427/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053427/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27711130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Ya-Ting</creatorcontrib><creatorcontrib>Tai, Cheng-Jeng</creatorcontrib><creatorcontrib>Chen, Chiehfeng</creatorcontrib><creatorcontrib>Wu, Hong-Cheng</creatorcontrib><creatorcontrib>Mikhaylichenko, Natalia</creatorcontrib><creatorcontrib>Chiu, Hsien-Tsai</creatorcontrib><creatorcontrib>Chen, Yun-Yi</creatorcontrib><creatorcontrib>Hsu, Yi-Hsin Elsa</creatorcontrib><title>Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL.
The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL.
Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia.
The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.</description><subject>Analysis</subject><subject>Biology and Life Sciences</subject><subject>Blood</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Comparative studies</subject><subject>Disease-Free Survival</subject><subject>Drug dosages</subject><subject>Effectiveness</subject><subject>Evidence-based medicine</subject><subject>FDA approval</subject><subject>Hematology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Lymphoma, T-Cell, Peripheral - therapy</subject><subject>Lymphomas</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Monoclonal antibodies</subject><subject>Neutropenia</subject><subject>Nitric-oxide synthase</subject><subject>Online searching</subject><subject>Patients</subject><subject>Public health</subject><subject>Radiation therapy</subject><subject>Recurrence</subject><subject>Research and Analysis Methods</subject><subject>Salvage</subject><subject>Salvage Therapy - methods</subject><subject>Stem cells</subject><subject>Surgery</subject><subject>Systematic review</subject><subject>T cells</subject><subject>T-cell lymphoma</subject><subject>Targeted cancer therapy</subject><subject>Thrombocytopenia</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk19v0zAUxSMEYmPwDRBYQkLw0GLH_xIekKox2KRJQ9vg1bpJrlNPSVzstNA3Pjru1k0r2gPJQ26c3zm2j3Oz7CWjU8Y1-3Dll2GAbrrwA04pU6xg7FG2z0qeT1RO-eN79V72LMYrSiUvlHqa7eVaM8Y43c_-HLt23q3JZ7fCEJEcWetqqNfEW3IB3QpaJJcBYexxGMk5ti4VkVgf0ksHi4gNua5tgHr0YU2-YXCLOQboyOXkELuOnK77xdz38JHMyMU6jtjD6OqkWTn89Tx7YqGL-GL7PMi-fzm6PDyenJ59PTmcnU5qVebjRMpGa6pFIYtSNYw2hZYcldIgaS1B1TwvpOA5rXJaCtBMylLzqrQVRSmt5AfZ6xvfReej2YYXDStyJUoqlErEyQ3ReLgyi-B6CGvjwZnrAR9aAyEtvENjlbUAumGszEUueLW5sLIVq0ClbJPXp-1sy6rHpk7hpUB2THe_DG5uWr8yMp2RyHUyeLc1CP7nEuNoehfrlCYM6JebdXPJFZWCJvTNP-jDu9tSLaQNuMH6NG-9MTUzoRNYClEkavoAle4Ge1enP826NL4jeL8jSMyIv8cWljGak4vz_2fPfuyyb--xc4RunEffLUfnh7gLihuwDj7GgPYuZEbNplFu0zCbRjHbRkmyV_cP6E502xn8LzKDDSk</recordid><startdate>20161006</startdate><enddate>20161006</enddate><creator>Yang, Ya-Ting</creator><creator>Tai, Cheng-Jeng</creator><creator>Chen, Chiehfeng</creator><creator>Wu, Hong-Cheng</creator><creator>Mikhaylichenko, Natalia</creator><creator>Chiu, Hsien-Tsai</creator><creator>Chen, Yun-Yi</creator><creator>Hsu, Yi-Hsin Elsa</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20161006</creationdate><title>Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review</title><author>Yang, Ya-Ting ; Tai, Cheng-Jeng ; Chen, Chiehfeng ; Wu, Hong-Cheng ; Mikhaylichenko, Natalia ; Chiu, Hsien-Tsai ; Chen, Yun-Yi ; Hsu, Yi-Hsin Elsa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-55d7707485896d10d8753e667a50c5a6c32854320b2094a7155973b9fb0e55f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Biology and Life Sciences</topic><topic>Blood</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Comparative studies</topic><topic>Disease-Free Survival</topic><topic>Drug dosages</topic><topic>Effectiveness</topic><topic>Evidence-based medicine</topic><topic>FDA approval</topic><topic>Hematology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Lymphoma, T-Cell, Peripheral - therapy</topic><topic>Lymphomas</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Monoclonal antibodies</topic><topic>Neutropenia</topic><topic>Nitric-oxide synthase</topic><topic>Online searching</topic><topic>Patients</topic><topic>Public health</topic><topic>Radiation therapy</topic><topic>Recurrence</topic><topic>Research and Analysis Methods</topic><topic>Salvage</topic><topic>Salvage Therapy - methods</topic><topic>Stem cells</topic><topic>Surgery</topic><topic>Systematic review</topic><topic>T cells</topic><topic>T-cell lymphoma</topic><topic>Targeted cancer therapy</topic><topic>Thrombocytopenia</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Ya-Ting</creatorcontrib><creatorcontrib>Tai, Cheng-Jeng</creatorcontrib><creatorcontrib>Chen, Chiehfeng</creatorcontrib><creatorcontrib>Wu, Hong-Cheng</creatorcontrib><creatorcontrib>Mikhaylichenko, Natalia</creatorcontrib><creatorcontrib>Chiu, Hsien-Tsai</creatorcontrib><creatorcontrib>Chen, Yun-Yi</creatorcontrib><creatorcontrib>Hsu, Yi-Hsin Elsa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Ya-Ting</au><au>Tai, Cheng-Jeng</au><au>Chen, Chiehfeng</au><au>Wu, Hong-Cheng</au><au>Mikhaylichenko, Natalia</au><au>Chiu, Hsien-Tsai</au><au>Chen, Yun-Yi</au><au>Hsu, Yi-Hsin Elsa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2016-10-06</date><risdate>2016</risdate><volume>11</volume><issue>10</issue><spage>e0161811</spage><epage>e0161811</epage><pages>e0161811-e0161811</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL.
The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL.
Of 35 records identified, a total of 14 studies were eligible for systematic reviews, and 12 different salvage regimens were investigated. A total of 618 relapsed/refractory PTCL patients were identified. The ORRs ranged from 22% for those treated with lenalidomide to 86% for those with brentuximab vedotin. By the three most frequent subtypes, the ORRs ranged from 14.2% to 71.5% for patients with the PTCL-NOS subtype, 8% to 54% for AITL subtypes, and 24% to 86% for the ALCL subtype. The medians of DOR, PFS, and OS ranged from 2.5 to 16.6 months, 2.6 to 13.3 months, and 3.6 to 14.5 months, respectively. The most frequently reported grade 3 or 4 adverse events (AEs) were hematological AEs, such as neutropenia and thrombocytopenia.
The efficacy of salvage therapy regimens is highly diverse for patients with relapsed/refractory PTCL; this heterogeneity in therapeutic effects might be due to the diversity in mechanisms, PTCL subtype distribution, and/or numbers/profiles of prior therapy. Comparative studies with matched pair analysis are warranted for more evidence of the salvage treatment effect on relapsed or heavily pretreated patients with PTCL.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>27711130</pmid><doi>10.1371/journal.pone.0161811</doi><tpages>e0161811</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2016-10, Vol.11 (10), p.e0161811-e0161811 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1826490466 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Analysis Biology and Life Sciences Blood Cancer therapies Care and treatment Chemotherapy Clinical trials Comparative studies Disease-Free Survival Drug dosages Effectiveness Evidence-based medicine FDA approval Hematology Hospitals Humans Internal medicine Lymphocytes T Lymphoma Lymphoma, T-Cell, Peripheral - therapy Lymphomas Medical research Medicine Medicine and Health Sciences Monoclonal antibodies Neutropenia Nitric-oxide synthase Online searching Patients Public health Radiation therapy Recurrence Research and Analysis Methods Salvage Salvage Therapy - methods Stem cells Surgery Systematic review T cells T-cell lymphoma Targeted cancer therapy Thrombocytopenia Transplants & implants Treatment Outcome |
| title | Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T22%3A46%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Highly%20Diverse%20Efficacy%20of%20Salvage%20Treatment%20Regimens%20for%20Relapsed%20or%20Refractory%20Peripheral%20T-Cell%20Lymphoma:%20A%20Systematic%20Review&rft.jtitle=PloS%20one&rft.au=Yang,%20Ya-Ting&rft.date=2016-10-06&rft.volume=11&rft.issue=10&rft.spage=e0161811&rft.epage=e0161811&rft.pages=e0161811-e0161811&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0161811&rft_dat=%3Cgale_plos_%3EA471829448%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826490466&rft_id=info:pmid/27711130&rft_galeid=A471829448&rft_doaj_id=oai_doaj_org_article_f6ffaa7d11924243bbbbbebfb1ba6771&rfr_iscdi=true |